[The influence of 0.85% RS-timolol and 0.5% S-timolol on intraocular pressure and systemic arterial blood pressure, heart rate, ECG, expiratory capacity in patients with ocular hypertension and primary open-angle glaucoma].
OBJECTIVE
Analysis of local and systemic effects of RS-timolol enantiomer and S-timolol in patients with ocular hypertension and glaucoma: evaluation of Risk/Benefit Ratio.


METHODS
19 patients (38 eyes) receiving 0.85% RS-timolol and 10 patients (20 eyes) receiving 0.5% S-timolol were evaluated using a double-blank test. Intraocular pressure, heart rate, systemic arterial blood pressure, ECG and spirometry were recorded before and 2 hours after drugs administration and after 7 days of treatment.


RESULTS
There were no statistically significant differences between intraocular pressure-lowering effects of RS-timolol and S-timolol. In patients receiving both medicines bradycardia was detected 2 hours after drugs administration. Patients receiving RS-timolol showed increased expiratory capacity in comparison to those receiving S-timolol. There was no detectable influence of both medicines on ECG and systemic arterial blood pressure.


CONCLUSIONS
0.85% RS-timolol and 0.5% S-timolol produced comparable intraocular pressure-lowering effects. 0.85% RS-timolol exerted less severe influence on respiratory system.
Czechowicz-Janicka
K
K
Kliniki Okulistyki Centrum Medycznego Kształcenia Podyplomowego w Warszawie.
Staszkiewicz
J
J
Strzałkowska
M
M
Krajewska
M
M
Popiołek
B
B
Christman
A
A
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects*; D004562:Electrocardiography; D005105:Expiratory Reserve Volume / Q000187:drug effects*; D005902:Glaucoma, Open-Angle / Q000150:complications / Q000175:diagnosis; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008875:Middle Aged; D009798:Ocular Hypertension / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D012720:Severity of Illness Index; D013999:Timolol / Q000494:pharmacology* / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D013999:Timolol